Literature DB >> 22183861

Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Chang Moo Kang1, Yong Eun Chung, Jeong Youp Park, Jin Sil Sung, Ho Kyoung Hwang, Hye Jin Choi, Hyunki Kim, Si Young Song, Woo Jung Lee.   

Abstract

BACKGROUND: Margin-negative pancreatectomy provides only chance to cure pancreatic cancer. However, borderline resectable pancreatic cancer (BRPCa) has the risk of incomplete palliative resection.
MATERIALS AND METHODS: We retrospectively reviewed 32 patients with BRPCa who underwent a pancreatectomy following preoperative chemoradiation therapy (CCRT (+)/Px group) and compared these patients with those with resectable pancreatic cancer (RPCa) who underwent pancreatectomy without preoperative CCRT (CCRT (-)/Px group, n=104).
RESULTS: Eighteen patients (56.2%) showed more than 50% significant pathological response to CCRT. The degree of pathological responses showed a positive relationship between final pT stage (p=0.075). More frequent vascular resection (p<0.001), transfusion (p=0.076), and longer operation time were observed in the CCRT(+)/Px group. However, similar R0 resection rates (p=0.272), lower pT stage (p<0.001), smaller number of metastastic lymph nodes (p=0.002), and lower incidence of lymph node metastasis (p=0.032) were noted in the CCRT(+)/Px group. The overall disease-specific survival were similar (median survival, 30.5 months (95% CI; 23.6-37.4) vs. 26.3 months (95% CI; 15.9-36.7), p=0.709), and no statistical differences in cancer recurrence risks were noted between the two groups (p=0.505).
CONCLUSION: Pancreatectomy following preoperative neoadjuvant CCRT can be a potential strategy for margin-negative resection in BRPCa patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22183861     DOI: 10.1007/s11605-011-1784-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  The impact of preoperative chemoradiotherapy on advanced low rectal cancer.

Authors:  Ping-Sheng Kao; Shih-Ching Chang; Ling-Wei Wang; Rheun-Chuan Lee; Wen-Yi Liang; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Jen-Kou Lin
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

Review 3.  Neoadjuvant therapy for pancreatic cancer.

Authors:  Andrew M Lowy
Journal:  J Gastrointest Surg       Date:  2008-02-08       Impact factor: 3.452

4.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

5.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer.

Authors:  Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

6.  CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.

Authors:  Woong Sub Koom; Jinsil Seong; Yong Bae Kim; Hae Ok Pyun; Si Young Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-28       Impact factor: 7.038

7.  Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.

Authors:  Paolo Massucco; Lorenzo Capussotti; Antonella Magnino; Elisa Sperti; Marco Gatti; Andrea Muratore; Enrico Sgotto; Pietro Gabriele; Massimo Aglietta
Journal:  Ann Surg Oncol       Date:  2006-09-06       Impact factor: 5.344

8.  Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.

Authors:  H Snady; H Bruckner; A Cooperman; J Paradiso; L Kiefer
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

Review 9.  Borderline resectable pancreatic cancer: on the edge of survival.

Authors:  Gregory M Springett; Sarah E Hoffe
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

10.  Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.

Authors:  Karl Y Bilimoria; Mark S Talamonti; Stephen F Sener; Malcolm M Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  J Am Coll Surg       Date:  2008-06-30       Impact factor: 6.113

View more
  28 in total

Review 1.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

Review 2.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer.

Authors:  Irene Epelboym; J DiNorcia; M Winner; M K Lee; J A Lee; B A Schrope; J A Chabot; J D Allendorf
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

4.  Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes.

Authors:  Sung Hwan Lee; Chang Moo Kang; Ho Kyoung Hwang; Sung Hoon Choi; Woo Jung Lee; Hoon Sang Chi
Journal:  Surg Endosc       Date:  2014-05-23       Impact factor: 4.584

Review 5.  Advances in chemotherapy for pancreatic cancer.

Authors:  Bhawna Sirohi; Ashish Singh; Shaheenah Dawood; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2015-01-13

Review 6.  Surgical management of pancreatic neoplasms: what's new?

Authors:  Andreas Karachristos; Nestor F Esnaola
Journal:  Curr Gastroenterol Rep       Date:  2014-08

Review 7.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

8.  Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

Authors:  Suzanne Russo; M Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2016-05-10       Impact factor: 4.409

Review 9.  Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?

Authors:  Daniel M Halperin; Gauri R Varadhachary
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

Review 10.  Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: current status and future perspectives.

Authors:  Chang Moo Kang; Sung Hwan Lee; Woo Jung Lee
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.